Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and FES PET/CT in Oligoprogressive ER+ Metastatic Breast Cancer
NCT06260033Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Jul 2024
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in breast cancer, sponsored by City of Hope. Primary endpoint: Proportion of patients that remain on their original systemic therapy for at least >= 24 weeks post stereotactic body radiation therapy (SBRT) treatment. Started Jul 2024; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06260033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06260033.